will medicare pay for glp 1 drugs CMS Issues Coverage Guidance on GLP-1 Anti-Obesity GLP-1 Drugs & Medicare in

Description

Am I a good candidate for GLP-1s

A GLP-1 receptor agonist medication may help patients with psoriasis.[ref] Related article: T Cell Exhaustion Asthma symptoms decrease: Asthma exacerbations also decreased in patients on GLP-1 receptor agonist medications.[ref] ( Related article : Asthma genes) Dementia and Alzheimers Prevention: In animal studies, infusions of GLP-1 decrease amyloid-beta levels and prevent neuronal cell death.[ref] Dysregulation of glucose entry into the brain is one hallmark of Alzheimers disease, tying together insulin resistance, GLP-1, and dementia.[ref][ref] GLP-1 receptor agonist drugs, such as liraglutide, are being studied for Alzheimers disease.[ref] Studies using data from diabetes patients showed a significant decrease in dementia for those on GLP-1s vs other diabetes medications

Meta-analyses in diabetic populations have found a correlation between reductions in HbA1c and GLP-1RA-mediated MACE risk reduction.[37, 38] The SELECT trial, which enrolled patients without diabetes but with pre-existing cardiovascular disease (CVD) and a BMI 27, found a significant reduction in MACE among those treated with semaglutide, leading to FDA approval for MACE reduction in individuals with established CVD.[18, 39] A meta-analysis incorporating SELECT and other CVOTs concluded that GLP-1RAs provide a significant MACE reduction in individuals without diabetes, though the reduction in individuals with diabetes is more pronounced.[12] These findings of benefit in populations without diabetes suggest that while the antihyperglycemic effects of GLP-1RAs likely contribute to MACE reduction, other mechanisms, such as systolic blood pressure reduction, likely also play a role.[40] Over time, clinical trials on GLP-1RA MACE reduction have shifted from a focus on secondary prevention, with over 80% of participants in earlier trials such as LEADER and SUSTAIN 6 having a history of established cardiovascular disease, to an emphasis on primary prevention in high risk participants, with less than a third of participants in REWIND having a history of established cardiovascular disease.[8, 10, 11, 41] While semaglutide is currently only FDA-approved for secondary prevention of cardiovascular disease, a meta-analysis of GLP-1RA outcome trials found no significant difference in cardiovascular event relative risk reduction between use for primary versus secondary prevention